Clinical trial
FR901228 in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
NCT00383565 · National Cancer Institute (NCI), NIH · Terminated
Key facts
| NCT number | NCT00383565 |
|---|---|
| Title | FR901228 in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma |
| Official title | A Phase II Study of Depsipeptide, a Histone Deacetylase Inhibitor, in Relapsed or Refractory Mantle Cell or Diffuse Large Cell Non-Hodgkin's Lymphoma |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Mantle Cell Lymphoma |
| Intervention type | Drug |
| Interventions | romidepsin |
| Enrollment | 9 |
| Start date | Sep 1, 2006 |
| Primary completion | Apr 1, 2011 |
| Completion | Apr 1, 2011 |
| First posted | Oct 3, 2006 |
| Last update posted | May 20, 2014 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: